Table 3 Type and duration (median and interquartile range in years) of treatments among study patients (N = 60)

bDMARD (N = 56)

2.2 (0 – 3.9)

4.25 (2.5 – 5.4)

5.1 (3.4 – 8.5)

Anakinra (N = 32)

1.15 (0.3 – 5.0)

2.95 (0.9 – 3*)

1.1 (0.6 – 2.4)

Canakinumab (N = 25)

2.1 (1.0 – 3.6)

3.6 (1.1 – 3.6*)

3.8 (0.9 – 6.0)

Tocilizumab (N = 33)

3.4 (2.9 – 4.6)

3.3 (1.0 – 4.5)

4.7 (2.5 – 6.6)

Glucocorticoids (N = 60)

0.5 (0.2 – 1)

1.1 (0.4 – 4.3)

2.6 (1 – 4.9)

sDMARD (N = 40)

0 (0 – 0.05)

0.3 (0 – 0.95)

4.1 (0.9 – 6.1)